Free Trial
NASDAQ:TELO

Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis

Telomir Pharmaceuticals logo
$1.18 0.00 (0.00%)
As of 11:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Telomir Pharmaceuticals Stock (NASDAQ:TELO)

Key Stats

Today's Range
$1.16
$1.22
50-Day Range
$1.15
$2.75
52-Week Range
$1.13
$8.40
Volume
40,706 shs
Average Volume
175,824 shs
Market Capitalization
$34.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Strong Buy

Company Overview

Telomir Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

TELO MarketRank™: 

Telomir Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 510th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Telomir Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Telomir Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Telomir Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Telomir Pharmaceuticals are expected to grow in the coming year, from ($0.40) to ($0.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Telomir Pharmaceuticals is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Telomir Pharmaceuticals is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Telomir Pharmaceuticals has a P/B Ratio of 58.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Telomir Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    12.12% of the float of Telomir Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Telomir Pharmaceuticals has recently decreased by 8.73%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Telomir Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Telomir Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.12% of the float of Telomir Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Telomir Pharmaceuticals has recently decreased by 8.73%, indicating that investor sentiment is improving significantly.
  • Search Interest

    3 people have searched for TELO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Telomir Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
Receive TELO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TELO Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
TELO Rises on Promising Telomir-1 Preclinical Results
See More Headlines

TELO Stock Analysis - Frequently Asked Questions

Telomir Pharmaceuticals' stock was trading at $4.12 at the beginning of 2025. Since then, TELO stock has decreased by 71.5% and is now trading at $1.1750.

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) posted its quarterly earnings data on Monday, May, 12th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03.

Telomir Pharmaceuticals (TELO) raised $7 million in an initial public offering (IPO) on Friday, February 9th 2024. The company issued 1,000,000 shares at $7.00 per share. Kingswood Investments acted as the underwriter for the IPO.

Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/12/2025
Today
7/10/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TELO
Previous Symbol
NASDAQ:TELO
CIK
1971532
Fax
N/A
Employees
1
Year Founded
N/A

Price Target and Rating

High Price Target
$15.00
Low Price Target
$15.00
Potential Upside/Downside
+1,176.6%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.53 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-2,009.40%
Return on Assets
-1,009.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.75
Quick Ratio
0.75

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.02 per share
Price / Book
58.75

Miscellaneous

Outstanding Shares
29,763,000
Free Float
N/A
Market Cap
$34.97 million
Optionable
N/A
Beta
-0.90
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:TELO) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners